Pharmacokinetics of coagulation factors: Clinical relevance for patients with haemophilia

Clinical Pharmacokinetics

Volumn 40, Issue 11, 2001, Pages 815-832

  Björkman, Sven ^a   Berntorp, Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; VON WILLEBRAND FACTOR;

BLEEDING; BOLUS INJECTION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; STEADY STATE;

ANIMALS; BLOOD COAGULATION FACTORS; GENE THERAPY; HEMOPHILIA A; HEMORRHAGE; HUMANS;

EID: 0035189391     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140110-00003     Document Type: Review

References (143)

1. Definitions in hemophilia
2. Clinical use of recombinant FVIIa
3. Calculations of factor VIII in vivo recovery and half-life
4. Principles of in vivo recovery and survival studies
5. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia
6. Factor IX concentrates for clinical use
7. Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation
8. The pharmacokinetics of factor VIII and factor IX: Methodology, pitfalls and applications
9. Factor VIII concentrates
10. Immunoaffinity purification of factor VIII
11. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ
12. Biochemical and in vivo properties of high purity factor IX concentrates
13. Recombinant factor IX
14. Therapeutic concentrates for the treatment of congenital deficiencies of factors VII, XI and XIII
15. Methodology of the one-stage assay of factor VIII (VIII: C)
16. Methods
17. Factor VII in an industrial population
18. Methodology of the two-stage assay of factor VIII (VIII:C)
19. Assay of factor VIII:C with a chromogenic substrate
20. Development of a sensitive and rapid chromogenic factor IX assay for clinical use
21. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
22. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment
23. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods
24. In vitro and in vivo characterization of factor VIII preparations
25. Factor VIII:C (FVIII:C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A: Comparison of one-stage assay, two-stage assay and a chromogenic substrate assay
26. Assay discrepancies with highly purified factor VIII concentrates
27. Pharmacokinetics of factor VIII in humans: Obtaining clinically relevant data from comparative studies
28. Potency and in vivo recovery of high purity factor VIII concentrates
29. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M
30. Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay
31. Potency estimation of recombinant factor VIII: Effect of assay method and standard
32. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates
33. In vivo recovery with products of very high purity-assay discrepancies
34. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII
35. The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma
36. The design and analysis of half-life and recovery studies for factor VIII and factor IX
37. A note on the calculation of recovery for factor VIII infusions
38. Comparison of factor VIII concentrates in non-bleeding patients
39. Heparin small pool high yield purified factor VIII: In vivo recovery and half-life of routinely produced freeze-dried concentrate
40. Kinetic evaluation of four factor VIII concentrates by model-independent methods
41. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates
42. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate
43. Biological regulation of factor VIII activity
44. The life cycle of coagulation factor VIII in view of its structure and function
45. 125iodine-labeled factor VIII in normals and patients with classic hemophilia
46. A mathematical model of coagulation factor VIII kinetics
47. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): Estimation of the rate of factor VIIIC synthesis
48. Kinetics of factor VIII-von Willebrand factor association
49. Stabilization of factor VIII in plasma by the von Willebrand factor
50. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease
51. Pharmacokinetics and hemostatic effect of different factor VIIl/von Willebrand factor concentrates in von Willebrand's disease type III
52. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in pa- tients with severe von Willebrand disease
53. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels
54. Haemostatic factors in human peripheral afferent lymph
55. Effect of altered plasma protein binding on apparent volume of distribution
56. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC
57. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
58. Development and small-scale production of a severely heated factor VIII concentrate
59. Recombinant. B-domain deleted factor VIII (r-VIIISQ): Pharmacokinetics and initial safety aspects in hemophilia A patients
60. Continuous intravenous infusion of factor VIII in classic haemophilia
61. Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals
62. The pharmacokinetics of recombinant factor VIII
63. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® M)
64. A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A
65. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods
66. The use of continuous infusion of factor concentrates in the treatment of hemophilia
67. In vivo recovery and early half-life of infused factor VIII in haemophilia A
68. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: A possible role for the half-life of transfused FVIII
69. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A
70. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
71. Effect of height and weight on the in vivo recovery of transfused factor VIII C
72. Prediction of the normal blood volume. Relation of blood volume to body habitus
73. Binding of coagulation factors IX and X to the endothelial cell surface
74. Binding of factors IX and IXa to cultured vascular endothelial cells
75. Treatment of hemophilia B with a new clotting-factor concentrate
76. Comparative single-dose pharmacokinetic study of Alphanine vs. Profilnine
77. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate
78. Clinical evaluation of recombinant factor IX
79. Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis
80. Variability of in vivo recovery of Factor IX after infusion of monoclonal antibody purified Factor IX concentrates in patients with hemophilia B
81. Dosing and monitoring NovoSeven® treatment
82. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
83. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol
84. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study
85. Pharmacokinetics of recombinant activated factor VII (rFVIIa)
86. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency
87. Successive factor VIII doses for a hemophiliac undergoing major surgery calculated on a microcomputer
88. A calculator program for individualizing factor VIII dosage
89. Individualization of factor VIII dosage
90. Pharmacokinetic dosing in prophylactic treatment of hemophilia A
91. Multidose pharmacokinetics of factor IX: Implications for dosing in prophylaxis
92. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B
93. Prophylactic use of factor VIII: An economic evaluation
94. Hemophilia prophylaxis with factor VIII concentrate
95. Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: A controlled study
96. The management of patients with coagulation factor deficiencies
97. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia
98. Dose requirement for replacement therapy in hemophilia A
99. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients
100. Safety and efficacy of an albumin-free formulated, B-domain deleted recombinant factor VIII (BBDrFVIII, r-VIII SQ) in previously treated patients (PTPs). A four-year update
101. Hematologic management of hemophilia A for surgery
102. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations
103. Continuous infusion of factor VIII for surgery and major bleeding
104. A pharmacokinetic model for factor VIII dosing during active haemorrhage in patients with haemophilia A
105. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A
106. Monoclonal purified F VIII for continuous infusion: Stability, microbiological safety and clinical experience
107. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery
108. AHF related protein in clinical praxis
109. Increased ristocetin-cofactor in acute myocardial infarction: A component of the acute phase reaction
110. Influence of spinal and general anaesthesia on haemostasis during total hip arthroplasty
111. Coagulation and fibrinolytic parameters in patients undergoing total hip replacement: Influence of the anaesthesia technique
112. The feasibility of using concentrates containing factor IX for continuous infusion
113. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery
114. Efficacy and safety of continuous infusion of Mononine® during five surgical procedures in three hemophilic patients
115. Recombinant factor IX (BeneFix) by adjusted continuous infusion: A study of stability, sterility and clinical experience
116. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A
117. Feasibility of using recombinant factor VIIa in continuous infusion
118. Experiences with continuous infusion of recombinant activated factor VII
119. Complications of hemophilia A treatment: Factor VIII inhibitors
120. Treatment of factor VIII inhibitors
121. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
122. Safety and immunogenicity of recombinant factor VIII (Recombinate™) in previously untreated patients (PUPs): A 6.5 year update
123. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years
124. Factor IX inhibitors in haemophilia B patients: Their incidence and prospects for development with high purity factor IX products
125. A more uniform measurement of factor VIII inhibitors
126. Immunosuppressive treatment in haemophiliacs with inhibitors
127. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients
128. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII
129. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A
130. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
131. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction
132. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay
133. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies
134. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors
135. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
136. Elimination of a major inhibitor epitope in factor VIII
137. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
138. Extravascular administration of factor IX: Potential for replacement therapy of canine and human hemophilia B
139. Oral treatment of haemophilia A by gastrointestinal absorption of factor VIII entrapped in liposomes
140. Gene transfer as an approach to treating hemophilia
141. The canine factor VIII cDNA and 5′-flanking sequence
142. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A